487 related articles for article (PubMed ID: 28636344)
1. Ruthenium Complexes are pH-Activated Metallo Prodrugs (pHAMPs) with Light-Triggered Selective Toxicity Toward Cancer Cells.
Qu F; Park S; Martinez K; Gray JL; Thowfeik FS; Lundeen JA; Kuhn AE; Charboneau DJ; Gerlach DL; Lockart MM; Law JA; Jernigan KL; Chambers N; Zeller M; Piro NA; Kassel WS; Schmehl RH; Paul JJ; Merino EJ; Kim Y; Papish ET
Inorg Chem; 2017 Jul; 56(13):7519-7532. PubMed ID: 28636344
[TBL] [Abstract][Full Text] [Related]
2. Singlet Oxygen Formation vs Photodissociation for Light-Responsive Protic Ruthenium Anticancer Compounds: The Oxygenated Substituent Determines Which Pathway Dominates.
Qu F; Lamb RW; Cameron CG; Park S; Oladipupo O; Gray JL; Xu Y; Cole HD; Bonizzoni M; Kim Y; McFarland SA; Webster CE; Papish ET
Inorg Chem; 2021 Feb; 60(4):2138-2148. PubMed ID: 33534562
[TBL] [Abstract][Full Text] [Related]
3. Sterically demanding methoxy and methyl groups in ruthenium complexes lead to enhanced quantum yields for blue light triggered photodissociation.
Qu F; Martinez K; Arcidiacono AM; Park S; Zeller M; Schmehl RH; Paul JJ; Kim Y; Papish ET
Dalton Trans; 2018 Nov; 47(44):15685-15693. PubMed ID: 30285013
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release.
Hufziger KT; Thowfeik FS; Charboneau DJ; Nieto I; Dougherty WG; Kassel WS; Dudley TJ; Merino EJ; Papish ET; Paul JJ
J Inorg Biochem; 2014 Jan; 130():103-11. PubMed ID: 24184694
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake of protic ruthenium complexes is influenced by pH dependent passive diffusion and energy dependent efflux.
Park S; Gray JL; Altman SD; Hairston AR; Beswick BT; Kim Y; Papish ET
J Inorg Biochem; 2020 Feb; 203():110922. PubMed ID: 31775072
[TBL] [Abstract][Full Text] [Related]
6. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
7. π-Expansive Heteroleptic Ruthenium(II) Complexes as Reverse Saturable Absorbers and Photosensitizers for Photodynamic Therapy.
Wang L; Yin H; Jabed MA; Hetu M; Wang C; Monro S; Zhu X; Kilina S; McFarland SA; Sun W
Inorg Chem; 2017 Mar; 56(6):3245-3259. PubMed ID: 28263079
[TBL] [Abstract][Full Text] [Related]
8. Reversible pH-Responsive Behavior of Ruthenium(II) Arene Complexes with Tethered Carboxylate.
Martínez-Peña F; Infante-Tadeo S; Habtemariam A; Pizarro AM
Inorg Chem; 2018 May; 57(9):5657-5668. PubMed ID: 29688005
[TBL] [Abstract][Full Text] [Related]
9. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
[TBL] [Abstract][Full Text] [Related]
10. Ru
Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
[TBL] [Abstract][Full Text] [Related]
11. Mixed-Ligand Cobalt(III) Complexes of a Naturally Occurring Coumarin and Phenanthroline Bases as Mitochondria-Targeted Dual-Purpose Photochemotherapeutics.
Sarkar T; Kumar A; Sahoo S; Hussain A
Inorg Chem; 2021 May; 60(9):6649-6662. PubMed ID: 33855849
[TBL] [Abstract][Full Text] [Related]
12. Half-sandwich ruthenium(ii) complexes containing N^N-chelated imino-pyridyl ligands that are selectively toxic to cancer cells.
Tian M; Li J; Zhang S; Guo L; He X; Kong D; Zhang H; Liu Z
Chem Commun (Camb); 2017 Nov; 53(95):12810-12813. PubMed ID: 29143019
[TBL] [Abstract][Full Text] [Related]
13. Ruthenium Complexes with Protic Ligands: Influence of the Position of OH Groups and π Expansion on Luminescence and Photocytotoxicity.
Oladipupo OE; Prescott MC; Blevins ER; Gray JL; Cameron CG; Qu F; Ward NA; Pierce AL; Collinson ER; Hall JF; Park S; Kim Y; McFarland SA; Fedin I; Papish ET
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983054
[TBL] [Abstract][Full Text] [Related]
14. Heteroleptic mononuclear compounds of ruthenium(ii): synthesis, structural analyses, in vitro antitumor activity and in vivo toxicity on zebrafish embryos.
Lenis-Rojas OA; Fernandes AR; Roma-Rodrigues C; Baptista PV; Marques F; Pérez-Fernández D; Guerra-Varela J; Sánchez L; Vázquez-García D; Torres ML; Fernández A; Fernández JJ
Dalton Trans; 2016 Dec; 45(47):19127-19140. PubMed ID: 27868117
[TBL] [Abstract][Full Text] [Related]
15. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
16. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
[TBL] [Abstract][Full Text] [Related]
17. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic Ruthenium(II) Complexes Containing a Dangling Pyridine: Selectivity for Diseased Cells Mediated by pH-Dependent DNA Binding.
Sangeetha S; Murali M
Inorg Chem; 2022 Feb; 61(6):2864-2882. PubMed ID: 35099196
[TBL] [Abstract][Full Text] [Related]
19. New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent.
Guerriero A; Oberhauser W; Riedel T; Peruzzini M; Dyson PJ; Gonsalvi L
Inorg Chem; 2017 May; 56(10):5514-5518. PubMed ID: 28443659
[TBL] [Abstract][Full Text] [Related]
20. Isostructural dinuclear phenoxo-/acetato-bridged manganese(II), cobalt(II), and zinc(II) complexes with labile sites: kinetics of transesterification of 2-hydroxypropyl-p-nitrophenylphosphate.
Arora H; Barman SK; Lloret F; Mukherjee R
Inorg Chem; 2012 May; 51(10):5539-53. PubMed ID: 22536852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
